SciBase

Day 2 of #WinterClinicalMiami The U.S. Team (Charmaine Winslow , Laura Mays , Michelle Lucas, Diana Redruello and Head of U.S. Leda Marie Beaty) and SciBase CEO Pia Renaudin are having a very productive day filled with meetings and attendees visiting the Nevisense Booth eager to learn more about how the power of EIS and Augmented Intelligence can enhance their practice and never miss a melanoma! If you are in #miami make sure to stop by and say hi 👋🏼!

#WC2025 is about to kick off in Miami! Our U.S. team is ready to engage with the dermatology community and discuss how the power of EIS and Augmented Intelligentence can enhance early melanoma detection in their practice. Give your patients the “golden touch” they deserve! Make sure to visit us at the SciBase Nevisense booth! #dermsquared #winterclinical #miami #melanoma #melanomadetectiom #EIS #AI #nevisense #scibase

We are happy to welcome Dirk Jahn to our German SciBase team! With over 20 years of experience in medical technology and a business administration degree from IHK, Dirk brings plenty of expertise and professionalism to his new role. Based in Dresden, Saxony, Dirk will be managing our Northeast Germany region, connecting with healthcare professionals, and helping to bring innovative skin health solutions. His passion for field service, meeting new people, and offering meaningful, patient-centric products like Nevisense— make him a strong addition to our team! Connect with Dirk to learn more about Nevisense or to schedule a meeting! #scibase #nevisense #growth #innovation #dermatology #skinhealth

Discover the latest trends in preclinical and clinical testing, join us at Cosmetotest on the 14th and 15th of may in Lyon! Contact Jeremy Bost to learn more or schedule a meeting! #scibase #nevisense #skinbarrier #skinhealth

Penser by Carnegie acted as sole global co-ordinator and bookrunner in the capital raise, consisting of a rights issue of units and a directed issue of units corresponding to SEK 53.4 million in SciBase. SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. #penserbycarnegie

Dermsquared’s Winter Clinical Dermatology Conference kicks off in just a few days in Miami! SciBase is a proud sponsor of this meeting and is looking forward to to engaging with the dermatology community. Are you attending? Let’s schedule a time to meet! Join the growing number of dermatologists utilizing the power of EIS and augmented intelligence for early melanoma detection! #dermsquared #winterclinical #miami #melanoma #melanomadetection #skincancer #skinhealth

We’re happy to announce SciBase participation in this year’s upcoming Cosmetotest! Join us in Lyon on the 14th and 15th of May, a great opportunity to learn more about #Nevisense and it’s abilities in cosmetic testing. #scibase #nevisense #cosmetotest2025 #beautytesting #clinicaltrials #cosmetinLyon

The Mayo Clinic is conducting a pilot study of SciBase’s Nevisense. https://lnkd.in/d4Rxn63q

We are happy to announce that The Mayo Clinic, the leading U.S. hospital, will initiate a pilot with Nevisense for AI-driven pigmented lesion workflows! Nevisense is the only FDA-approved device for point-of-care skin cancer detection in the U.S. Read the press release in full: https://lnkd.in/dBRQy9Ts #SkinCancerDetection #AI #Nevisense #Dermatology #scibase #earlydetection

Today, December 27, 2024, is the first day of the subscription period in SciBase Holding AB's rights issue of units, consisting of new shares and warrants. Over the past year, SciBase has advanced its positions significantly and the rights issue will lay the foundation for continued growth and innovation. Subscription Period: December 27, 2024 – January 13, 2025  For more information and terms: https://lnkd.in/d22DqgKw #SciBase #Innovation #Growth #RightsIssue #Nevisense